Caris Life Sciences (CAI) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.05
- Estimate
- $0.02
- Surprise
- +148.5%
- Revenue (period 2026-09-30)
- $275.4M
- Score today
- 5.8/10
Revenue source: xbrl.
How the report landed
Caris Life Sciences (CAI) beat the $0.02 estimate with adjusted EPS of $0.05 — a large 148.5% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates CAI Sell at 5.8/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +148.5% surprise compares with a +79.3% four-quarter average.
What argues against it
- Concentration risk — Product: MI Profile tissue-based profiling (84.4%)
- Concentration risk — Supplier: sole suppliers for next-generation sequencers
- Cyclical trap - fwd PE 89x vs trail 20x (4.5x)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $33.22
- Stop
- $30.89
Forward estimates sit below the trailing run-rate (89.3× forward vs 19.7× trailing) — consensus expects earnings to decline from here.
Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.
CAI at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $9.39B
- P/E (fwd)
- 89.3
- P/E (ttm)
- 19.7
- 52-week range
- $14.19–$36.50
- Off 52-week high
- 9.0%
- RSI (14)
- 56
- Volume vs avg
- 1.21×
- Score today
- 5.8/10